Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.

Burkina Faso Immunization schedule Measles vaccine Meningococcal serogroup A conjugate vaccine Vaccination challenges Vaccine introduction

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
15 10 2021
Historique:
received: 22 05 2021
revised: 13 09 2021
accepted: 14 09 2021
pubmed: 29 9 2021
medline: 26 10 2021
entrez: 28 9 2021
Statut: ppublish

Résumé

In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15-18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children. Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February-March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis. We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers' motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15-18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2. MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination.

Sections du résumé

BACKGROUND
In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15-18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children.
METHODS
Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February-March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis.
RESULTS
We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers' motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15-18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2.
CONCLUSIONS
MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination.

Identifiants

pubmed: 34579975
pii: S0264-410X(21)01229-9
doi: 10.1016/j.vaccine.2021.09.038
pmc: PMC8519392
mid: NIHMS1748112
pii:
doi:

Substances chimiques

Meningococcal Vaccines 0
Vaccines, Conjugate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6370-6377

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Vaccine. 2017 Oct 27;35(45):6059-6069
pubmed: 28974409
Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214
pubmed: 32730103
BMC Pregnancy Childbirth. 2020 Sep 16;20(1):541
pubmed: 32938428
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S225-S232
pubmed: 31671449
Glob Health Promot. 2014 Mar;21(1):76-87
pubmed: 24496777
Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):341-53
pubmed: 10674069
Vaccines (Basel). 2020 Aug 27;8(3):
pubmed: 32867126
Lancet Infect Dis. 2012 Oct;12(10):757-64
pubmed: 22818241
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S233-S243
pubmed: 31671442
Can Commun Dis Rep. 2020 Apr 02;46(4):93-97
pubmed: 32281992
Med Anthropol Q. 2016 Jun;30(2):203-21
pubmed: 25624042
BMC Public Health. 2018 Mar 6;18(1):324
pubmed: 29510684
Psychol Health. 2018 Jun;33(6):746-764
pubmed: 29132225
Euro Surveill. 2019 Sep;24(36):
pubmed: 31507265
Wkly Epidemiol Rec. 2015 Feb 20;90(8):57-62
pubmed: 25702330
Global Health. 2016 Nov 15;12(1):72
pubmed: 27846857
Vaccine. 2018 Jul 16;36(30):4517-4524
pubmed: 29907485
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S451-8
pubmed: 26553674
BMC Int Health Hum Rights. 2009 Oct 14;9 Suppl 1:S9
pubmed: 19828067
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S410-5
pubmed: 26553668
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S140-S147
pubmed: 31671448
Vaccine. 2014 Nov 12;32(48):6505-12
pubmed: 25261379
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S165-S174
pubmed: 31671441
Vaccine. 2018 Nov 26;36(49):7445-7455
pubmed: 30377064
Pan Afr Med J. 2017 Jun 21;27(Suppl 3):4
pubmed: 29296139
Vaccine. 2012 Oct 5;30(45):6347-58
pubmed: 22940378
Med Mal Infect. 2006 Mar;36(3):138-43
pubmed: 16581215
J Immunol Sci. 2018 Jul 28;Suppl:113-121
pubmed: 30766972
BMC Public Health. 2020 Feb 19;20(1):254
pubmed: 32075630

Auteurs

Brooke Noel Aksnes (BN)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Jenny A Walldorf (JA)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Sylvain F Nkwenkeu (SF)

UNICEF Ouagadougou, Burkina Faso.

Robert L Zoma (RL)

Institut National de Statistique et Démographie, Ouagadougou, Burkina Faso.

Imran Mirza (I)

UNICEF, New York, NY 10017, USA.

Felix Tarbangdo (F)

Davycas International, Ouagadougou, Burkina Faso.

Soukeynatou Fall (S)

UNICEF Ouagadougou, Burkina Faso.

Sansan Hien (S)

UNICEF Ouagadougou, Burkina Faso.

Cesaire Ky (C)

Ministère de la Santé, Ouagadougou, Burkina Faso.

Ludovic Kambou (L)

Ministère de la Santé, Ouagadougou, Burkina Faso.

Alpha Oumar Diallo (AO)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Flavien H Aké (FH)

Davycas International, Ouagadougou, Burkina Faso.

Cynthia Hatcher (C)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Jaymin C Patel (JC)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Ryan T Novak (RT)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Terri B Hyde (TB)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Isaïe Medah (I)

Ministère de la Santé, Ouagadougou, Burkina Faso.

Heidi M Soeters (HM)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA. Electronic address: HMSoeters@cdc.gov.

Mohamed F Jalloh (MF)

Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH